中国DOAC患者药物基因组多态性与出血及血栓栓塞风险的相关性
该回顾性研究纳入720例接受达比加群、利伐沙班或艾多沙班治疗的非瓣膜性房颤中国患者,采用Cox回归比较关键单核苷酸多态性携带者与非携带者的临床结局。结果显示CES1 rs2244613 C等位基因与达比加群使用者出血事件减少相关,ABCB1 rs1045642 T等位基因与利伐沙班使用者血栓栓塞风险降低相关。
要点
- CES1 rs2244613 C等位基因与达比加群使用者出血事件减少相关。
- ABCB1 rs1045642 T等位基因与利伐沙班使用者血栓栓塞风险降低相关。
- SLCO1B1 rs4149056 C等位基因与艾多沙班使用者出血风险呈接近统计学意义的趋势。
核心结论
- CES1 rs2244613和ABCB1 rs1045642等位基因分别与中国患者服用达比加群和利伐沙班后的结局事件相关。
- 上述发现有助于预测中国DOAC使用者的临床结局并制定个体化抗凝治疗策略。
研究设计与样本
- 回顾性研究纳入720例接受达比加群、利伐沙班或艾多沙班治疗的非瓣膜性房颤中国患者。
- 采用Cox回归模型比较关键单核苷酸多态性携带者与非携带者的临床结局。
临床怎么用
- 对使用达比加群的中国非瓣膜性房颤患者,可关注CES1 rs2244613 C等位基因以评估出血风险。
- 对使用利伐沙班的中国非瓣膜性房颤患者,可关注ABCB1 rs1045642 T等位基因以评估血栓栓塞风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Gene polymorphisms play a critical role in the variability of plasma concentrations of direct-acting oral anticoagulants (DOACs). In this study, we aimed to investigate the effects of genetic variants on the clinical outcomes of Chinese patients treated with DOACs. METHODS: The retrospective study recruited 720 patients with nonvalvular atrial fibrillation who were receiving dabigatran, rivaroxaban or edoxaban. Cox regression models were employed to compare the clinical outcomes between carriers and noncarriers of the key single nucleotide polymorphisms. RESULTS: Results revealed that the CES1 rs2244613 C allele significantly reduced bleeding events in patients treated with dabigatran (adjusted hazard ratio 0.33, 95% confidence interval 0.13-0.85, P = .021). The carriage of ABCB1 rs1045642 T allele was associated with a lower risk of thromboembolism in rivaroxaban users (adjusted hazard ratio 0.19, 95% confidence interval 0.07-0.57, P = .003). Additionally, a trend toward statistical significance (P = .052) was observed between the SLCO1B1 rs4149056 C allele and bleeding risk among the edoxaban users. CONCLUSIONS: Our study showed that the CES1 rs2244613 and ABCB1 rs1045642 alleles were associated with outcome events in Chinese patients taking dabigatran and rivaroxaban, respectively. The findings could help predict clinical outcomes and develop personalized anticoagulation treatment strategies for Chinese patients taking DOACs.
引用
- Wang D, An Y, Zhou X, et al. Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct-acting oral anticoagulants. Br J Clin Pharmacol. 2025. PMID: 40400080. doi:10.1002/bcp.70078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。